NanoValent Pharmaceuticals

Nanovalent Pharmaceuticals, a privately-held company based in Bozeman, MT, is developing a unique targeted nanosphere (TNS) platform with emerging product candidates to improve the delivery, safety, and performance of cancer and other therapeutics. The company is collaborating with Children's Hospital Los Angeles and other academic partners, and its lead product, NV103, is approaching IND status with plans for clinical trials in 2026. Nanovalent has an experienced management team and strong clinical and operational capabilities, and is currently seeking Series A financing in 2024.